Online inquiry

IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13887MR)

This product GTTS-WQ13887MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDGFRB gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002609.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5159
UniProt ID P09619
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13887MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9960MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA KBSA301
GTTS-WQ14164MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ6005MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CNTO 095
GTTS-WQ1206MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABP 980
GTTS-WQ9933MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA KB-004
GTTS-WQ15742MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA VX-15
GTTS-WQ10609MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY3300054
GTTS-WQ12488MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NN-8226
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW